PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The end of a dogma: the safety of doxycycline use in young children for malaria treatment.

Abstract Anti-malarial drug resistance to chloroquine and sulfadoxine-pyrimethamine has spread from Southeast Asia to Africa. Furthermore, the recent emergence of resistance to artemisinin-based combination therapy (ACT) in Southeast Asia highlights the need to identify new anti-malarial drugs. Doxycycline is recommended for malaria chemoprophylaxis for travel in endemic areas, or in combination with the use of quinine for malaria treatment when ACT is unavailable or when the treatment of severe malaria with artesunate fails. However, doxycycline is not used in young children under 8 years of age due to its contraindication due to the risk of yellow tooth discolouration and dental enamel hypoplasia. Doxycycline was developed after tetracycline and was labelled with the same side-effects as the earlier tetracyclines. However, recent studies report little or no effects of doxycycline on tooth staining or dental enamel hypoplasia in children under 8 years of age. In the United States, the Centers for Disease Control and Prevention have recommended the use of doxycycline for the treatment of acute and chronic Q fever and tick-borne rickettsial diseases in young children. It is time to rehabilitate doxycycline and to recommend it for malaria treatment in children under 8 years of age.
PMID
Related Publications

UK malaria treatment guidelines 2016.

Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Tetracyclines in malaria.

Combined antimalarial therapy using artemisinin.

UK malaria treatment guidelines.

Authors

Mayor MeshTerms

Drug-Related Side Effects and Adverse Reactions

Keywords

Anti-malarial drug

Antibiotics

Children

Doxycycline

Malaria

Plasmodium falciparum

Prophylaxis

Resistance

Treatment

Journal Title malaria journal
Publication Year Start




PMID- 28407772
OWN - NLM
STAT- MEDLINE
DA  - 20170414
DCOM- 20170501
LR  - 20170501
IS  - 1475-2875 (Electronic)
IS  - 1475-2875 (Linking)
VI  - 16
IP  - 1
DP  - 2017 Apr 13
TI  - The end of a dogma: the safety of doxycycline use in young children for malaria
      treatment.
PG  - 148
LID - 10.1186/s12936-017-1797-9 [doi]
AB  - Anti-malarial drug resistance to chloroquine and sulfadoxine-pyrimethamine has
      spread from Southeast Asia to Africa. Furthermore, the recent emergence of
      resistance to artemisinin-based combination therapy (ACT) in Southeast Asia
      highlights the need to identify new anti-malarial drugs. Doxycycline is
      recommended for malaria chemoprophylaxis for travel in endemic areas, or in
      combination with the use of quinine for malaria treatment when ACT is unavailable
      or when the treatment of severe malaria with artesunate fails. However,
      doxycycline is not used in young children under 8 years of age due to its
      contraindication due to the risk of yellow tooth discolouration and dental enamel
      hypoplasia. Doxycycline was developed after tetracycline and was labelled with
      the same side-effects as the earlier tetracyclines. However, recent studies
      report little or no effects of doxycycline on tooth staining or dental enamel
      hypoplasia in children under 8 years of age. In the United States, the Centers
      for Disease Control and Prevention have recommended the use of doxycycline for
      the treatment of acute and chronic Q fever and tick-borne rickettsial diseases in
      young children. It is time to rehabilitate doxycycline and to recommend it for
      malaria treatment in children under 8 years of age.
FAU - Gaillard, Tiphaine
AU  - Gaillard T
AD  - Federation des Laboratoires, Hopital d'Instruction des Armees Desgenettes, Lyon, 
      France.
FAU - Briolant, Sebastien
AU  - Briolant S
AD  - Unite de Parasitologie et d'Entomologie, Departement des Maladies Infectieuses,
      Institut de Recherche Biomedicale des Armees, HIA Laveran, Boulevard Laveran,
      13013, Marseille, France.
AD  - Aix Marseille Universite, Unite de Recherche sur les Maladies Infectieuses et
      Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Institut
      Hospitalo-universitaire Mediterranee Infection, Marseille, France.
FAU - Madamet, Marylin
AU  - Madamet M
AD  - Unite de Parasitologie et d'Entomologie, Departement des Maladies Infectieuses,
      Institut de Recherche Biomedicale des Armees, HIA Laveran, Boulevard Laveran,
      13013, Marseille, France.
AD  - Aix Marseille Universite, Unite de Recherche sur les Maladies Infectieuses et
      Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Institut
      Hospitalo-universitaire Mediterranee Infection, Marseille, France.
AD  - Centre National de Reference du Paludisme, Marseille, France.
FAU - Pradines, Bruno
AU  - Pradines B
AD  - Unite de Parasitologie et d'Entomologie, Departement des Maladies Infectieuses,
      Institut de Recherche Biomedicale des Armees, HIA Laveran, Boulevard Laveran,
      13013, Marseille, France. [email protected]
AD  - Aix Marseille Universite, Unite de Recherche sur les Maladies Infectieuses et
      Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Institut
      Hospitalo-universitaire Mediterranee Infection, Marseille, France.
      [email protected]
AD  - Centre National de Reference du Paludisme, Marseille, France.
      [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170413
PL  - England
TA  - Malar J
JT  - Malaria journal
JID - 101139802
RN  - 0 (Antimalarials)
RN  - N12000U13O (Doxycycline)
SB  - IM
MH  - Antimalarials/*adverse effects/*therapeutic use
MH  - Chemoprevention/adverse effects/methods
MH  - Child
MH  - Child, Preschool
MH  - Dental Enamel Hypoplasia/*chemically induced
MH  - Doxycycline/*adverse effects/*therapeutic use
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Malaria/*drug therapy
PMC - PMC5390373
OTO - NOTNLM
OT  - Anti-malarial drug
OT  - Antibiotics
OT  - Children
OT  - Doxycycline
OT  - Malaria
OT  - Plasmodium falciparum
OT  - Prophylaxis
OT  - Resistance
OT  - Treatment
EDAT- 2017/04/15 06:00
MHDA- 2017/05/02 06:00
CRDT- 2017/04/15 06:00
PHST- 2016/11/21 [received]
PHST- 2017/04/04 [accepted]
AID - 10.1186/s12936-017-1797-9 [doi]
AID - 10.1186/s12936-017-1797-9 [pii]
PST - epublish
SO  - Malar J. 2017 Apr 13;16(1):148. doi: 10.1186/s12936-017-1797-9.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>